Diabetes mellitus have become the third leading chronic disease among the population, following cancer and cardiovascular disease (CVD). Animal models, especially mouse models, can be used as suitable research tools for diabetes. Ace Therapeutics can provide mouse models of T1DM to accelerate customer research progress.
Type 1 Diabetes Mellitus (T1DM) is an autoimmune disease, which may be caused by genes or the autoimmune system. The β-cells in patients have been damaged, clinically manifested as insulin secretion disorder, increased blood sugar and ketosis tendency.
Whether your group is looking to screen compounds to identify a lead candidate or dive deeper into mechanism-of-action studies, our T1DM mouse models are useful tools. Metabolixis has extensive experience in establishing chemically induced diabetic mice/rat models for our global customers, especially for the high fat diet/STZ induced diabetic model.
The type 1 diabetes model induced by streptozotocin (STZ) in rats and mice has many similarities with human type 1 diabetes in clinical manifestations, course of the disease, and morphological changes of the pancreatic islet. Streptozotocin (STZ), which has a specific damaging effect on animal pancreatic islet B cells, is the most widely used chemical inducer for animal models of diabetes.
NOD mouse models are an inbred, genetically well-characterized mouse strain. Female mice have a propensity to develop T1DM via an autoimmune pathway, making them particularly useful for dissecting the immunologic aspects and the role of immune tolerance in the development of T1DM.
In addition, if you want to have disease models for your own research needs, we can provide T1DM modeling service for you.
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.